Data-Driven Drug Discovery Platform "RePhaIND^®" to be Presented at the Pharmaceutical Society of Japan Annual Meeting

株式會社 GEXVal
2025年3月14日 

 

Data-Driven Drug Discovery Platform "RePhaIND^®︎" to be Presented at the Pharmaceutical Society of Japan Annual Meeting

 

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that Chief Technology Officer (CTO) Yusuke Nakayama, Ph.D., will present innovative applications of its proprietary next-generation drug discovery platform "RePhaIND"⁽¹⁾ at the 145th Annual Meeting of the Pharmaceutical Society of Japan⁽²⁾ - Promoting the Pharmaceutical Ecosystem: Creating Future Innovation through Cross-disciplinary Collaboration, to be held in Fukuoka, Japan from March 26 to 29, 2025.

GEXVal pioneers the application of cutting-edge artificial intelligence (AI) technologies, specifically Graph Attention Network (GAT) and Graph Attention Autoencoder (GATE) ⁽³⁾, to the field of drug discovery. We are challenging the status quo through innovative technology development and clinical advancement that explores new possibilities and brings a paradigm shift to conventional drug discovery processes.

RePhaIND^®(2) is a proprietary data-driven drug discovery platform developed by GEXVal that creates new value in pharmaceutical development. By leveraging innovative AI technology to understand complex relationships in pharmaceutical research—such as interactions between drug candidate compounds and their target molecules, and disease mechanisms—as "connections" for AI learning, this platform enables the creation of novel pharmaceutical solutions that would be difficult to identify through conventional methods.

RePhaIND^®accelerates the creation of new drug discovery projects and brings a paradigm shift to the drug discovery process. In this presentation, we will report on our innovative analytical methods and case studies utilizing Graph Neural Networks (GNNs)⁽³⁾.

Key Points of the Presentation: The presentation will cover three main aspects of our research:

1. Introduction of our proprietary data-driven drug discovery platform "RePhaIND^®"⁽²⁾, integrating large-scale biomedical data
2. Implementation of GNNs⁽³⁾ to accelerate drug discovery and drive a paradigm shift in the drug discovery and development processes
3. Demonstration of platform effectiveness through COVID-19 therapeutic candidate pilot program

"With the advancement of AI technology, drug discovery research is entering a new phase," says Dr. Nakayama. "We are honored to have this opportunity to present at this annual meeting where researchers from both academia and the pharmaceutical industry gather. We look forward to discussing the possibilities of AI, in particular the applications of GNNs⁽³⁾ in drug discovery and sharing both the technical innovation and practical value of our RePhaIND^®(2) platform with experts in the field."

GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology (RePhaIND^®(2)), we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

**Presentation Details**

Conference	The 145th Annual Meeting of the Pharmaceutical Society of Japan
URL	The 145th Annual Meeting of the Pharmaceutical Society of Japan
Date	March 28, 2025, 16:45-18:09
Venue	Fukuoka International Congress Center, Fukuoka, Japan / Room 8 (409+410 [4F])
Session	Information and Computational Chemistry (Session will be conducted in Japanese)
Chairs	Associate Professor Noriyuki Yamaotsu (Kitasato University) Associate Professor Hiroaki Saito (Hokuriku University)
Abstract No	28-08-pm22
Title	Data-driven drug discovery using Graph Neural Networks: Identification of therapeutic candidates for COVID-19

 

1) About the Pharmaceutical Society of Japan

Established in 1880, the Pharmaceutical Society of Japan is the country's oldest academic society. It represents Japan's pharmaceutical research community with approximately 15,000 members from academic institutions and pharmaceutical industry.
For details: https://www.pharm.or.jp

2) About RePhaIND^®：Revolutionary Pharmacoinformatics to Find IND (Investigational New Drug)

Powered by RePhaIND^® - EMPOWER・ACCELERATE・REVOLUTIONIZE Drug Discovery
RePhaIND^® is GEXVal's proprietary AI-driven drug discovery platform with three key features:

EMPOWER: Discover hidden relationships between drug candidates and diseases
ACCELERATE: Dramatically improve efficiency compared to conventional methods
REVOLUTIONIZE: Enable new approaches to unmet medical needs, particularly in rare diseases, bringing a paradigm shift to the drug discovery process

RePhaIND^® is a registered trademark of GEXVal Inc. in Japan, China, Hong Kong, Korea, Australia, Europe, UK, and US and a trademark in other countries and regions.

3) About Graph Neural Networks (GNNs)

Graph Neural Networks (GNNs) are AI technologies that learn patterns from various "connections" in data. In particular, Graph Attention Network (GAT) is widely used in everyday services such as social media recommendations and logistics route optimization. Notably, Graph Attention Autoencoder (GATE), which GEXVal pioneered in drug discovery, has previously been limited to specific applications in life sciences, such as protein structure prediction. By innovatively applying GATE technology to the entire drug discovery process, GEXVal enables the discovery of novel therapeutic candidates that would otherwise remain unidentified through conventional methods.

 

有關本事宜請諮詢:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com